Aptevo Therapeutics Inc. 8-K

What Happened

• On May 6, 2026, Aptevo Therapeutics Inc. (APVO) announced new clinical results from its RAINIER frontline acute myeloid leukemia (AML) trial in a press release (attached as Exhibit 99.1 to the Form 8-K).
• The company said it is on track to complete the Phase 1b dose‑optimization trial and to select the recommended Phase 2 dose this year. The planned Phase 2 will dose mipletamig in combination with venetoclax and azacitidine.

Key Details

• Filing date: May 6, 2026; press release included as Exhibit 99.1.
• Program: RAINIER frontline AML trial evaluating mipletamig.
• Near-term milestone: completion of Phase 1b dose optimization and selection of recommended Phase 2 dose in 2026.
• Planned Phase 2 regimen: mipletamig combined with venetoclax and azacitidine.
• Form 8-K signed by Daphne Taylor, Senior VP & Chief Financial Officer.

Why It Matters

• Clinical readouts and an on-track timeline for dose selection are material development milestones that clarify Aptevo’s pathway toward a larger Phase 2 trial.
• For investors, confirmation of a 2026 dose-selection milestone sets a nearer-term catalyst (trial advancement and potential future data releases); the filing does not include financial results or other corporate changes.